Search Results

LifeSpan Vision Ventures announced an investment in Deciduous Therapeutics, a pioneering longevity biotechnology company dedicated to enhancing human healthspan by developing innovative medicines targeting the elimination of senescent cells through restoring endogenous immune mechanisms.

QuantalX Neuroscience, a leading medical device company specializing in Brain Health diagnosis, is thrilled to announce a significant partnership with The Sheba Longevity Center, part of the prestigious Sheba Medical Center, Israel.

Eyenovia’s stock craters to its lowest point in its six-year lifespan as a public company following the biotech’s termination of its lead program in pediatric progressive myopia due to lack of efficacy.

Rejuvenate Bio today announced publication of groundbreaking research in the peer-reviewed journal Cellular Reprogramming.

MyMD Pharmaceuticals ® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1 ® as a Therapy for Delaying Aging and Extending Healthy Lifespan.

MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced further advancement in its fully-funded, multi-center Phase 2 clinical trial of lead drug candidate MYMD-1® as a therapy for delaying aging and expanding healthy lifespan.

Celularity, Inc., a clinical-stage biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, shared that Chairperson, Founder and Chief Executive Officer Robert J. Hariri, M.D., Ph.D. addressed the Future Investment Initiative 6th Edition in Riyadh conference sponsored by the Future Investment Initiative at the plenary session: The Science and Technology for Extending Healthy Human Lifespan.

Cambrian Biopharma announced an oversubscribed $100 million Series C. The biotech aims to prevent age-related diseases and increase healthy lifespans.